Direct Inhibition of Renin

Abstract

-

Keywords

• Renin angiotensin system, direct renin inhibitors, aliskiren, plasma renin activity

Direk Renin İnhibisyonu

Öz

Renal ekstraktlar ile renin anjiotensin sisteminin 1898’de ortaya konmasıyla başlayan tarihi süreci hala şaşırtıcı olmaya devam ediyor. Anjiyotensin dönüştürücü enzim inhibitörleri (ACEI) ve anjiyoten- sin reseptör blokerlerinden (ARB) sonra, son zaman- larda direkt renin inhibitörleri (DRI) de renin anjiyoten- sin alanına girdi. Giderek artan kanıtlarla, renin anji- otensin sistemi inhibisyonu hipertansiyon tadevisinde önemli bir tedavi stratejisidir. Özgün hasta grupları üzerinde ve son organ hasarını korumaya odaklanan sürmekte olan ve gelecekte yapılacak klinik calışma- ların sonuçları, direkt renin inhibisyonu hakkındaki bilgi birikimimizi ve anlayışımızı zenginleştirecektir

Anahtar Kelimeler

• Renin anjiyotensin sistemi, direkt renin inhibitörleri, aliskiren, plazma renin aktivitesi.

References

1. Basso N, Terragno NA. History about the discovery of the renin-angiotensin system. Hypertension 2001;38:1246-9.
2. Luft FC. A brief history of renin. J Mol Med 2008;86:611-3.
3. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008;7:399-410.
4. Siragy HM, Kar S, Kirkpatrick P. Aliskiren: news and analy- sis. Nature Reviews Drug Discovery 2007;6:779-80.
5. Uresin Y, Mehtar Bozkurt M, Sabirli S, Ozunal ZG. Aliskiren, the future of renin-angiotensin system blockade? Expert Rev Cardiovasc Ther 2007;5:835-49.
6. Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006;1:221-8.
7. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocar- dial infarction in hypertensive patients. Am J Hypertens 1997;10:1-8.
8. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, et al. Aliskiren, a human renin inhibitor, amelio- rates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76.

9. Vaidyanathan S, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, et al. Pharmacokinetics, safety, and toler- ability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007;47:453-60.
10. Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combina- tion in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-8.
11. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsar- tan in patients with hypertension: a randomised, double- blind trial. Lancet 2007;370:221-9.
12. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26.
13. Munger MA, Drummond W, Essop MR, Maboudian M, Khan M, Keefe DL. Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur Heart J Suppl 2006;27:717-84.